# Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

> **NCT04717375** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 125 (actual)

## Conditions studied

- Cancer
- Neoplasm

## Interventions

- **DRUG:** SAR444881
- **DRUG:** Pembrolizumab
- **DRUG:** Cetuximab
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT04717375
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-11
- **Primary completion:** 2025-07-02
- **Final completion:** 2025-07-02
- **Target enrollment:** 125 (ACTUAL)
- **Why stopped:** Early discontinuation based on strategic sponsor decision not driven by any safety concerns
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04717375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04717375, "Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04717375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*